MetaCap

ImmunityBio Stock Forecast

NASDAQ: IBRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

6.02-0.55 (-8.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IBRX analyst consensus

Consensus (4 analysts)

strong_buy

Avg. price target

$14.25+136.71%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $16.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

What analysts say

According to 4 Wall Street analysts covering ImmunityBio (2026-11-17), 4 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $14.25, with a high estimate of $16.00 and a low estimate of $12.00. The average target implies upside of 136.7% from the current price of $6.02.

The spread between the highest and lowest targets is 33.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for IBRX.

Summary generated from market data by MetaCap's automated system. Methodology

Rating distribution

ImmunityBio analyst rating distribution
RatingAnalystsShare
Strong buy125%
Buy375%
Hold00%
Sell00%
Strong sell00%

Ratings as of 2026-11-17.

Price target scenarios

Price targets versus the current price
TargetPricevs. current
Low target$12.00+99.34%
Average target$14.25+136.71%
High target$16.00+165.78%

How analysts view ImmunityBio's peers

Peer analyst targets
CompanyConsensusPriceAvg. targetImplied move
KODstrong_buy97.17$129.50+33.27%
IMVTbuy31.77$48.63+53.07%
SRRKstrong_buy48.13$70.06+45.56%
TWSTbuy103.32$128.82+24.68%
CGONstrong_buy79.47$109.69+38.03%
ADPTstrong_buy27.93$33.86+21.23%

Related